• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

20.07.2017

NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma

JERUSALEM--(BUSINESS WIRE)--Jul. 20, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the National Institute for Health and Care Excellence (NICE) in England has recommended CINQAERO® (reslizumab) in its Final Appraisal Determination (FAD). CINQAERO® is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment. “Despite the availability of current treatment options, many patients with...
13.07.2017

Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders

JERUSALEM--(BUSINESS WIRE)--Jul. 13, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier today. Shareholders voted to approve the elections of Murray Goldberg, Roberto Mignone, Dr. Perry Nisen and Nechemia (Chemi) Peres to the Company’s Board of Directors. "We greatly appreciate the support of Teva's shareholders as we work to strengthen the leadership of Teva, with the addition of these distinguished Board members, and our ongoing search to find the best chief executive officer to lead Teva,” stated Dr. Sol Barer, Cha...
11.07.2017

Teva to Report Second Quarter 2017 Financial Results on August 3, 2017

JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its second quarter 2017 financial results on Thursday, August 3, 2017 at 6:30 a.m. ET. Teva will host a conference call and live webcast on the same day, at 7:30 a.m. ET to discuss its second quarter 2017 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-869-2321; Canada 1-866-766-8269 or Internation...
11.07.2017

Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology

Data support overnight conversion from tetrabenazine to AUSTEDO™ for the treatment of chorea associated with Huntington disease JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and the Huntington Study Group today announced results from the Phase III open-label, single-arm switch cohort of the ARC-HD (Alternatives for Reducing Chorea in HD) study were published in JAMA Neurology. Results from the study showed patients with chorea associated with Huntington disease (HD) were able to safely switch overnight from three times daily tetrabenazine to twice daily AUSTEDO™ (d...
29.06.2017

Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)

INCHEON, South Korea & JERUSALEM--(BUSINESS WIRE)--Jun. 29, 2017-- Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for CT-P10, a proposed Monoclonal Antibody (mAb) biosimilar to Rituxan®1 (rituximab), which is used to treat patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. “As the global leader in biosimilars wh...
29.06.2017

Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia

JERUSALEM--(BUSINESS WIRE)--Jun. 29, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of results from the Phase III study, AIM-TD (Addressing Involuntary Movements in Tardive Dyskinesia), in the medical journal, The Lancet Psychiatry. The AIM-TD study evaluated the safety, efficacy and tolerability of the investigational use of fixed-dose deutetrabenazine (SD-809) compared to placebo for the treatment of tardive dyskinesia (TD). “TD is a chronic condition that affects patients who are suffering from primary psychiatric illnesses, which are already debilitating and can...
27.06.2017

Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Jun. 27, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN). TV-45070 did not meet the primary endpoint of a statistically significant change in pain from baseline to week four as assessed by the numeric rating scale (NRS). Secondary endpoints were also not met. There were no safety concerns in the study. This was a Phase II proof of concept study seeking to understand the potential for a topical ...
12.06.2017

Teva Announces Launch of Generic Zetia® in the United States

JERUSALEM--(BUSINESS WIRE)--Jun. 12, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Zetia®1 (ezetimibe) tablets, 10 mg, in the U.S. Ezetimibe is a prescription medicine used to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe tablets are for patients who cannot control their cholesterol levels by diet and exercise alone. It can be used by itself or with other medicines to treat high cholesterol. Ezetimibe tablets work to reduce the amount of cholesterol the body absorbs. According to the American ...
09.06.2017

Teva Announces Exclusive Launch of Generic Pataday® in the United States

JERUSALEM--(BUSINESS WIRE)--Jun. 9, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Pataday®1 (olopatadine hydrochloride ophthalmic solution) 0.2%, in the U.S. Olopatadine hydrochloride ophthalmic solution 0.2% is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis. Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on t...
07.06.2017

Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention

Statistically and clinically significant results demonstrate fremanezumab's efficacy and safety, including unique quarterly subcutaneous dosing regimen, and in patients already on preventive therapy Follows positive results in chronic migraine announced by Teva last week, together representing major advance in the development of new treatment options for the millions of patients who suffer from this debilitating disease Teva’s Phase III HALO program now complete, encompassing more than 2000 patients, meeting all 25 primary and secondary analyses across both monthly and quarterly dosing regimens in episodic ...